Charles River Laboratories
Charles River Laboratories International, Inc., commonly known as Charles River, is a leading provider of essential products and services for the pharmaceutical and biotechnology industries. Headquartered in the United States, the company operates extensively across North America, Europe, and Asia, offering a global reach that enhances its service delivery. Founded in 1947, Charles River has achieved significant milestones, including the expansion of its preclinical and clinical services. The company specialises in drug discovery, safety assessment, and laboratory services, providing unique solutions that streamline the research process. Its commitment to innovation and quality has solidified its position as a trusted partner in the life sciences sector. With a robust portfolio that includes in vivo and in vitro testing, Charles River Laboratories is recognised for its expertise and reliability, making it a preferred choice for organisations seeking to advance their research and development efforts.
DitchCarbon Score
How does Charles River Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Charles River Laboratories's score of 53 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Charles River Laboratories's reported carbon emissions
In 2023, Charles River Laboratories reported total greenhouse gas emissions of approximately 85723000 kg CO2e for Scope 1, 18031000 kg CO2e for Scope 2, and a significant 435589000 kg CO2e for Scope 3 emissions. This brings their combined Scope 1 and 2 emissions to about 102610000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 50% from a 2018 baseline by the year 2030. Additionally, they plan to decrease Scope 3 emissions by 15% from a 2019 baseline by the same year. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector. Charles River Laboratories is also focused on increasing its annual sourcing of renewable electricity from 1% in 2018 to 100% by 2030, further demonstrating its commitment to reducing its carbon footprint. The company’s emissions data and reduction targets are inherited from its parent organization, Charles River Laboratories International, Inc., ensuring a cohesive approach to climate action across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Charles River Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
